Press Releases

Press Releases

Neumentum Confirms Type B Meeting with FDA and Announces New Chief Medical and Scientific Officers

Neumentum, a pharmaceutical company dedicated to transforming the way acute and chronic pain are treated – without opioids – today announced it has confirmed its Type B meeting with the U.S. Food and Drug Administration (FDA). The company also announced its appointment of Robert B. Raffa, Ph.D., as Chief Scientific Officer and Ilona Steigerwald, M.D., as Chief Medical Officer.